NCT01405235 - Study on Paclitaxel Plus Topotecan in Comparison With Topotecan Plus Cisplatin in Recurrent or Persistent Cervical Carcinoma | Biotech Hunter

Enrollment

312

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

June 30, 2012

Study Completion Date

January 31, 2015

Conditions

Recurrent, Persistent or Metastasized Cervical Cancer

Interventions

DRUG

Paclitaxel

Paclitaxel 70 mg/m2/d i.v. on Days 1, 8, and 15 in combination with Topotecan 1.75 mg/m2/d i.v. on Days 1, 8, and 15, q 28 d

DRUG

Cisplatin/Paclitaxel

Topotecan 0.75 mg/m2/d i.v. on Days 1- 3 in combination with Cisplatin 50 mg/m2 i.v. on Day 1, q 21 d

Trial Locations (1)

Universitätsfrauenklinik, Erlangen